| Literature DB >> 30143727 |
Jorge Rodriguez-Duarte1,2,3, Rosina Dapueto1,2,3, Germán Galliussi1,3, Lucía Turell4, Andrés Kamaid3,5, Nicholas K H Khoo6, Francisco J Schopfer6, Bruce A Freeman6, Carlos Escande3,7, Carlos Batthyány8,9,10, Gerardo Ferrer-Sueta11, Gloria V López12,13,14.
Abstract
Inflammation plays a major role in the onset and development of chronic non-communicable diseases like obesity, cardiovascular diseases and cancer. Combined, these diseases represent the most common causes of death worldwide, thus development of novel pharmacological approaches is crucial. Electrophilic nitroalkenes derived from fatty acids are formed endogenously and exert anti-inflammatory actions by the modification of proteins involved in inflammation signaling cascades. We have developed novel nitroalkenes derived from α-tocopherol aiming to increase its salutary actions by adding anti-inflammatory properties to a well-known nutraceutical. We synthesized and characterized an α-tocopherol-nitroalkene (NATOH) and two hydrosoluble analogues derived from Trolox (NATxME and NATx0). We analyzed the kinetics of the Michael addition reaction of these compounds with thiols in micellar systems aiming to understand the effect of hydrophobic partition on the reactivity of nitroalkenes. We studied NATxME in vitro showing it exerts non-conventional anti-inflammatory responses by inducing Nrf2-Keap1-dependent gene expression and inhibiting the secretion of NF-κB dependent pro-inflammatory cytokines. NATxME was also effective in vivo, inhibiting neutrophil recruitment in a zebrafish model of inflammation. This work lays the foundation for the rational design of a new therapeutic strategy for the prevention and treatment of metabolic and inflammation-related diseases.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30143727 PMCID: PMC6109136 DOI: 10.1038/s41598-018-31218-7
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Synthesis of novel nitroalkene analogues of α-tocopherol. (A) Synthesis of NATOH and NATxME; (B) Synthesis of NATx0.
Figure 2Reaction of synthetic nitroalkenes with nucleophiles in different environments. (A) Spectral change upon reaction of 10 µM NATOH with 0.1 mM βME in TMA20 buffer at pH 8.1 containing 2.5 g/L SDS. (B) First-order plots obtained at different concentrations of βME measuring absorbance at 350 nm. (C) Second-order plot for the same experiment, linear fit parameters kf (slope) = 2.3 M−1 s−1, kr (intercept) = 5 × 10−3 s−1. (D) Spectral change upon titration of NATOH in CHAPS micelles. The arrows indicate the change upon increase in pH of the bulk solution. (E) Titration curves of NATOH at 350 nm in TMA20 buffer and different micelle suspensions, from left to right, CTAB, CHAPS, Triton X-100 and SDS. The absorbance was normalized to the acidic and alkaline extrapolated values of the fit. (F) Apparent pK results of NATOH and NATxME in different micellar media.
Rate constants of nucleophilic addition of NATOH and NATxME to GSH and β-ME in micellar suspension and aqueous solution.
| Surfactant | NATOH | |||
|---|---|---|---|---|
| Electrophilic reactivity | ||||
| Thiol | pH | |||
| CTAB | GSH | 7.1 | 576 | 0.36 |
| β-ME | 7 | 343 | 0.13 | |
| CHAPS | GSH | 6.7 | 34 | 1.7 × 10−2 |
| 7.0 | 100 | 4 × 10−2 | ||
| 7.3 | 148 | 6.2 × 10−2 | ||
| β-ME | 6.9 | 53 | 9.9 × 10−3 | |
| 7.1 | 83 | 1.5 × 10−2 | ||
| 8.3 | 383 | 0.15 | ||
| Triton X-100 | GSH | 7.1 | 0.8 | N.D. |
| β-ME | 7 | 6.5 | 1.8 × 10−3 | |
| SDS | GSH | 7.2 | 0.2 | |
| β-ME | 7.5 | 0.63 | 3 × 10−4 | |
| 7.8 | 1.0 | 4.9 × 10−4 | ||
| 8.1 | 2.3 | 5 × 10−3 | ||
|
| ||||
| None | GSH | 7.1 | 1370 | N.D. |
| β-ME | 7.1 | 349 | ||
|
| ||||
| None | GSH | 7.1 | 71 | N.D. |
| β-ME | 7.1 | 21 | ||
| GAPDH | 7.4 | 220 | ||
Addition rate constant of NATx0 to GSH, β-ME and GAPDH.
Figure 3NATxME anti-inflammatory and cytoprotective effects. NATxME inhibits the secretion of pro-inflammatory cytokines (A–C). RAW 264.7 macrophages were treated with NATxME 1, 3 and 10 µM for 2 h and then stimulated with LPS (50 ng/ml) for 18 h. The secretion of inflammatory cytokines MCP-1 (A), IL-6 (B) and TNF-α (C) was analyzed by ELISA in the supernatant. Values are shown as mean ± SD. Statistical analysis: one-way ANOVA Bonferroni’s multiple comparison test. (A) * = 0.0294; ** = 0.0017; **** < 0.0001. (B) ** = 0.013; **** < 0.0001. (C) * = 0.0131. vs. LPS. NATxME induces the Nrf2-Keap-1 system (D–F). Raw 264.7 macrophages were treated with NATxME 1, 3 and 10 µM for 5 h. The expression of NQO1 (D), GCLM (E) and HO-1 (F) were analyzed by quantitative RT-PCR. Values are shown as mean ± SD. Statistical analysis: one-way ANOVA Bonferroni’s multiple comparison test. (D) ** = 0.0038. (E) * = 0.0310; *** = 0.0001. (F) *** = 0.0001. vs control.
Figure 4NATxME inhibits neutrophil recruitment in zebrafish. (A) Diagram of acute inflammation assay. At 3 dpf zebrafish larvae were pre-treated for 2 h with DMSO, ibuprofen or NATxME. Wounding was performed in tail fins by transection with a scapel, and larvae were incubated again in the presence of drugs. Neutrophils at the site of injury were imaged and counted 4 h post transection. (B) Representative pictures used for quantification, corresponding to DMSO, 20 µM ibuprofen and 4 µM NATxME. Dotted rectangles indicate the wounded region of interest (ROI) where neutrophils were counted. (C) Quantification of neutrophil recruitment to wounded fins at 4 h under different treatments. Larvae number were: DMSO[40], 20 µM ibuprofen[17], 1 µM NATxME[33], 2.5 µM NATxME[32], 4 µM NATxME[17]. Statistical analysis: one-way ANOVA Bonferroni’s multiple comparison test, * = 0.0164; **** < 0.0001.